Lixte Biotechnology Holdings Inc./$LIXT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
Ticker
$LIXT
Sector
Primary listing
Employees
2
Headquarters
Website
LIXT Metrics
BasicAdvanced
$26M
-
-$1.27
0.48
-
Price and volume
Market cap
$26M
Beta
0.48
52-week high
$6.26
52-week low
$0.64
Average daily volume
161K
Financial strength
Current ratio
1.843
Quick ratio
1.652
Interest coverage (TTM)
-295.27%
Profitability
Management effectiveness
Return on assets (TTM)
-99.79%
Return on equity (TTM)
-213.21%
Valuation
Price to book
24.12
Price to tangible book (TTM)
24.12
Price to free cash flow (TTM)
-5.287
Free cash flow yield (TTM)
-18.91%
Free cash flow per share (TTM)
-1.078
Growth
Earnings per share change (TTM)
-30.21%
3-year earnings per share growth (CAGR)
-34.36%
10-year earnings per share growth (CAGR)
-9.20%
LIXT News
AllArticlesVideos
LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT)
Accesswire5 hours ago
LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)
Accesswire20 hours ago
24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor
Newsfile Corp2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lixte Biotechnology Holdings Inc. stock?
Lixte Biotechnology Holdings Inc. (LIXT) has a market cap of $26M as of September 16, 2025.
What is the P/E ratio for Lixte Biotechnology Holdings Inc. stock?
The price to earnings (P/E) ratio for Lixte Biotechnology Holdings Inc. (LIXT) stock is 0 as of September 16, 2025.
Does Lixte Biotechnology Holdings Inc. stock pay dividends?
No, Lixte Biotechnology Holdings Inc. (LIXT) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Lixte Biotechnology Holdings Inc. dividend payment date?
Lixte Biotechnology Holdings Inc. (LIXT) stock does not pay dividends to its shareholders.
What is the beta indicator for Lixte Biotechnology Holdings Inc.?
Lixte Biotechnology Holdings Inc. (LIXT) has a beta rating of 0.48. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.